SLBT

SL Science Holding Ltd

Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. E9· CIK 0002070534 Biotech & Drug Discovery

$1.23 +0.08 (+6.96%)

Oct 26 4:00 PM ET · prev $1.15

Market cap

$644.9M

Small cap

Next earnings

Nov 11

in 15 days

1 year

−88.2%

from $10.38 · Oct 28

30 days

−36.3%

from $1.93

52-week range

$1.15–12.81

−90% from high · low Oct 23

Avg volume 20D

49.6K

Oct 15 spike 130.7K

Short interest

36.6K

≈0.0% of shares · −28.9%

Days to cover

1.0

at average volume

Insider net

+$10.3T

1 buyer · 0 sellers · 12 mo

Filing reports

analyzed by SecBot

SecBot read MIXED 5 reports · 90 days

Balance 0 bearish · 0 bullish · 5 neutral oldest → newest, height = score

Avg score

·High conf. 4/5 ·Next Earnings date, Nov 11, 2026

Strongest NEUTRAL SL Science Holding Ltd (SLBT) filed its unaudited H1 2026 financial results via Form 6-K, reporting revenue…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

X Jul 31 Short interest jumps 89.2% to 106.6K
X Aug 14 Short interest falls 70.4% to 31.6K
X Sep 15 Short interest falls 28.9% to 26.8K
B Sep 29 1 insider buy $10.3T at $2,272,653.00
X Sep 30 Short interest jumps 92.3% to 51.5K
X Oct 15 Short interest falls 28.9% to 36.6K

Signal stack

Where each data set points today.

InsidersBULLISH

1 insider bought $10.3T. No open-market sales.
Short sellersCOVERING

Short interest −28.9% to 36.6K shares. 1.0 days to cover, ≈0.0% of shares.
TrendDOWNTREND

39% below its 50-day average. New closing low $1.15 on Oct 23.

Who's buying

13F

Top holder	Shares	Value
GEODE CAPITAL MANAGEMENT, LLC	193,404	$926.4K
JANE STREET GROUP, LLC	14,540	$69.6K
UBS Group AG	12,515	$59.9K
OSAIC HOLDINGS, INC.	286	$1.4K

Quarterly 13F filings are due 45 days after each quarter ends.

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Upcoming

Nov 11, 2026

Earnings date

SLBT Q3 2026 Earnings Scheduled — 2026-11-11

Recent

Oct 26, 2026

Earnings

SL Science Holding Limited Reports First Half 2026 Financial Results

Net revenue rose 23% to $1.39 million with gross margin expanding to 40.2%, driven by B2B distribution growth and reduction in purchase costs…

Sep 24, 2026

Company news

SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma

New findings highlight the therapy’s ability to preferentially destroy MGMT-positive tumor cells, the specific population that survives standard…

Aug 27, 2026

Press release

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

TAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered…

Aug 12, 2026

Earnings date

SLBT Q2 2026 Earnings Scheduled — 2026-08-12

Jul 17, 2026

Press release

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (γδ) T cells in eliminating…